Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237

1.

Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers.

Mallalieu NL, Winter E, Fettner S, Patel K, Zwanziger E, Attley G, Rodriguez I, Kano A, Salama SM, Bentley D, Geretti AM.

Antimicrob Agents Chemother. 2020 Feb 10. pii: AAC.02229-19. doi: 10.1128/AAC.02229-19. [Epub ahead of print]

2.

Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.

Stirrup OT, Asboe D, Pozniak A, Sabin CA, Gilson R, Mackie NE, Tostevin A, Hill T, Dunn DT; UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort.

HIV Med. 2020 Jan 11. doi: 10.1111/hiv.12829. [Epub ahead of print]

PMID:
31927793
3.

Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa.

Villa G, Abdullahi A, Owusu D, Smith C, Azumah M, Sayeed L, Austin H, Awuah D, Beloukas A, Chadwick D, Phillips R, Geretti AM.

EClinicalMedicine. 2020 Jan 5;18:100231. doi: 10.1016/j.eclinm.2019.12.001. eCollection 2020 Jan.

4.

Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV.

Stirrup OT, Sabin CA, Phillips AN, Williams I, Churchill D, Tostevin A, Hill T, Dunn DT; UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort .

J Virus Erad. 2019 Nov 4;5(4):204-211.

5.

Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey.

De Luca A, Pezzotti P, Boucher C, Döring M, Incardona F, Kaiser R, Lengauer T, Pfeifer N, Schülter E, Vandamme AM, Zazzi M, Geretti AM; EucoHIV Study Group.

PLoS One. 2019 Nov 21;14(11):e0225381. doi: 10.1371/journal.pone.0225381. eCollection 2019.

6.

Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group.

Bradshaw D, Mbisa JL, Geretti AM, Healy BJ, Cooke GS, Foster GR, Thomson EC, McLauchlan J, Agarwal K, Sabin C, Mutimer D, Moss P, Irving WL, Barnes E; Hepatitis C Trust, UK.

J Infect. 2019 Dec;79(6):503-512. doi: 10.1016/j.jinf.2019.10.007. Epub 2019 Oct 16. Review.

PMID:
31629015
7.

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.

Tzou PL, Rhee SY, Descamps D, Clutter DS, Hare B, Mor O, Grude M, Parkin N, Jordan MR, Bertagnolio S, Schapiro JM, Harrigan PR, Geretti AM, Marcelin AG, Shafer RW; WHO HIVResNet Working Groups.

J Antimicrob Chemother. 2020 Jan 1;75(1):170-182. doi: 10.1093/jac/dkz417.

PMID:
31617907
8.

Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis.

Lacoin L, Hurst M, Hill NR, Gordon J, Geretti AM, Aspinall R, Corless L, Gao-Du Y, Mistry L, Mutimer D.

BMJ Open. 2019 Aug 5;9(8):e029066. doi: 10.1136/bmjopen-2019-029066.

9.

An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy.

Geretti AM, Abdullahi A, Mafotsing Fopoussi O, Bonnett L, Defo VF, Moudourou S, Fokam J, Kouanfack C, Torimiro J.

J Antimicrob Chemother. 2019 Oct 1;74(10):3011-3015. doi: 10.1093/jac/dkz264.

PMID:
31299067
10.

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Raben D, Coll P, Antinori A, Nwokolo N, Rieger A, Prins JM, Blaxhult A, Weber R, Van Eeden A, Brockmeyer NH, Clarke A, Del Romero Guerrero J, Raffi F, Bogner JR, Wandeler G, Gerstoft J, Gutiérrez F, Brinkman K, Kitchen M, Ostergaard L, Leon A, Ristola M, Jessen H, Stellbrink HJ, Phillips AN, Lundgren J; PARTNER Study Group.

Lancet. 2019 Jun 15;393(10189):2428-2438. doi: 10.1016/S0140-6736(19)30418-0. Epub 2019 May 2.

11.

Corrigendum: Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor-Sparing Antiretroviral Therapy in a High-HBV Endemicity Setting.

Abdullahi A, Fopoussi OM, Torimiro J, Atkins M, Kouanfack C, Geretti AM.

Open Forum Infect Dis. 2019 Apr 3;6(4):ofz142. doi: 10.1093/ofid/ofz142. eCollection 2019 Apr.

12.

Being part of the solution.

Geretti AM.

Sex Transm Infect. 2019 Mar;95(2):81. doi: 10.1136/sextrans-2019-053994. No abstract available.

PMID:
30804221
13.

Hepatitis D prevalence: problems with extrapolation to global population estimates.

Stockdale AJ, Kreuels B, Henrion MRY, Giorgi E, Kyomuhangi I, Geretti AM.

Gut. 2020 Feb;69(2):396-397. doi: 10.1136/gutjnl-2018-317874. Epub 2018 Dec 19. No abstract available.

PMID:
30567743
14.

Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.

Geretti AM, White E, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin C, Dunn DT; UK HIV Drug Resistance Database and UK CHIC Study.

J Antimicrob Chemother. 2019 Mar 1;74(3):746-753. doi: 10.1093/jac/dky468.

15.

Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction.

Mbisa JL, Kirwan P, Tostevin A, Ledesma J, Bibby DF, Brown A, Myers R, Hassan AS, Murphy G, Asboe D, Pozniak A, Kirk S, Gill ON, Sabin C, Delpech V, Dunn DT; UK HIV Drug Resistance Database .

Clin Infect Dis. 2019 Sep 13;69(7):1136-1143. doi: 10.1093/cid/ciy1048.

16.

Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor-Sparing Antiretroviral Therapy in a High-HBV Endemicity Setting.

Abdullahi A, Fopoussi OM, Torimiro J, Atkins M, Kouanfack C, Geretti AM.

Open Forum Infect Dis. 2018 Oct 5;5(10):ofy251. doi: 10.1093/ofid/ofy251. eCollection 2018 Oct. Erratum in: Open Forum Infect Dis. 2019 Apr 03;6(4):ofz142.

17.

Point-of-Care Screening for a Current Hepatitis C Virus Infection: Influence on Uptake of a Concomitant Offer of HIV Screening.

Geretti AM, Austin H, Villa G, Hungerford D, Smith C, Davies P, Williams J, Beloukas A, Sawicki W, Hopkins M.

Sci Rep. 2018 Oct 17;8(1):15297. doi: 10.1038/s41598-018-33172-w.

18.

The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy.

Schultze A, Torti C, Cozzi-Lepri A, Vandamme AM, Zazzi M, Sambatakou H, De Luca A, Geretti AM, Sonnerborg A, Ruiz L, Monno L, Di Giambenedetto S, Gori A, Lapadula G; European Transmitted Drug Resistance collaboration (EU-TDR).

AIDS. 2019 Feb 1;33(2):315-326. doi: 10.1097/QAD.0000000000002046.

PMID:
30325769
19.

Epidemiology of hepatitis B, C and D in Malawi: systematic review.

Stockdale AJ, Mitambo C, Everett D, Geretti AM, Gordon MA.

BMC Infect Dis. 2018 Oct 12;18(1):516. doi: 10.1186/s12879-018-3428-7. Review.

20.

Incidence, aetiology, and sequelae of viral meningitis in UK adults: a multicentre prospective observational cohort study.

McGill F, Griffiths MJ, Bonnett LJ, Geretti AM, Michael BD, Beeching NJ, McKee D, Scarlett P, Hart IJ, Mutton KJ, Jung A, Adan G, Gummery A, Sulaiman WAW, Ennis K, Martin AP, Haycox A, Miller A, Solomon T; UK Meningitis Study Investigators.

Lancet Infect Dis. 2018 Sep;18(9):992-1003. doi: 10.1016/S1473-3099(18)30245-7. Epub 2018 Jun 29.

21.

A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action.

Mokaya J, McNaughton AL, Hadley MJ, Beloukas A, Geretti AM, Goedhals D, Matthews PC.

PLoS Negl Trop Dis. 2018 Aug 6;12(8):e0006629. doi: 10.1371/journal.pntd.0006629. eCollection 2018 Aug.

22.

Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring.

Villa G, Phillips RO, Smith C, Stockdale AJ, Ruggiero A, Beloukas A, Appiah LT, Chadwick D, Sarfo FS, Geretti AM.

J Antimicrob Chemother. 2018 Nov 1;73(11):3148-3157. doi: 10.1093/jac/dky281.

23.

Hepatitis C among vulnerable populations: A seroprevalence study of homeless, people who inject drugs and prisoners in London.

Aisyah DN, Shallcross L, Hayward A, Aldridge RW, Hemming S, Yates S, Ferenando G, Possas L, Garber E, Watson JM, Geretti AM, McHugh TD, Lipman M, Story A.

J Viral Hepat. 2018 Nov;25(11):1260-1269. doi: 10.1111/jvh.12936. Epub 2018 Jun 20.

PMID:
29851232
24.

Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV positive adults in Ghana.

Villa G, Phillips RO, Smith C, Stockdale AJ, Beloukas A, Appiah LT, Chadwick D, Ruggiero A, Sarfo FS, Post F, Geretti AM.

J Infect. 2018 Jun;76(6):515-521. doi: 10.1016/j.jinf.2018.03.001. Epub 2018 Apr 24.

25.

Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.

Stirrup OT, Dunn DT, Tostevin A, Sabin CA, Pozniak A, Asboe D, Cox A, Orkin C, Martin F, Cane P; UK HIV Drug Resistance Database; UK Collaborative HIV Cohort.

AIDS Res Ther. 2018 Apr 16;15(1):11. doi: 10.1186/s12981-018-0198-7.

26.

State of the Art in HIV Drug Resistance: Science and Technology Knowledge Gap.

Boucher CA, Bobkova MR, Geretti AM, Hung CC, Kaiser R, Marcelin AG, Streinu-Cercel A, van Wyk J, Dorr P, Vandamme AM.

AIDS Rev. 2018 Jan-Mar;20(1):27-42. Review.

PMID:
29628515
27.

Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy.

Ruggiero A, Cozzi-Lepri A, Beloukas A, Richman D, Khoo S, Phillips A, Geretti AM; ERAS Study Group.

Open Forum Infect Dis. 2018 Feb 3;5(2):ofy032. doi: 10.1093/ofid/ofy032. eCollection 2018 Feb.

28.

High prevalence of latent tuberculosis and bloodborne virus infection in a homeless population.

Aldridge RW, Hayward AC, Hemming S, Yates SK, Ferenando G, Possas L, Garber E, Watson JM, Geretti AM, McHugh TD, Lipman M, Story A.

Thorax. 2018 Jun;73(6):557-564. doi: 10.1136/thoraxjnl-2016-209579. Epub 2018 Jan 29.

29.

HIV gp120 in the Lungs of Antiretroviral Therapy-treated Individuals Impairs Alveolar Macrophage Responses to Pneumococci.

Collini PJ, Bewley MA, Mohasin M, Marriott HM, Miller RF, Geretti AM, Beloukas A, Papadimitropoulos A, Read RC, Noursadeghi M, Dockrell DH.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1604-1615. doi: 10.1164/rccm.201708-1755OC.

30.

Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis.

Stockdale AJ, Saunders MJ, Boyd MA, Bonnett LJ, Johnston V, Wandeler G, Schoffelen AF, Ciaffi L, Stafford K, Collier AC, Paton NI, Geretti AM.

Clin Infect Dis. 2018 Jun 1;66(12):1846-1857. doi: 10.1093/cid/cix1108.

31.

Epidemiological data for hepatitis D in Africa - Authors' reply.

Stockdale AJ, Beloukas A, Geretti AM.

Lancet Glob Health. 2018 Jan;6(1):e34. doi: 10.1016/S2214-109X(17)30464-3. No abstract available. Erratum in: Lancet Glob Health. 2018 Feb;6(2):e151.

32.

Promoting high standards of care for women living with HIV: position statement from the Women Against Viruses in Europe Working Group.

Kowalska JD, Aebi-Popp K, Loutfy M, Post FA, Perez-Elias MJ, Johnson M, Mulcahy F; Women Against Viruses in Europe (WAVE) Working Group.

HIV Med. 2018 Feb;19(2):167-173. doi: 10.1111/hiv.12565. Epub 2017 Nov 21. Review.

33.

Hepatitis C Virus (HCV) RNA screening and sequencing using dry plasma spots.

Geretti AM, King S, Adjei-Asante K, Appiah LT, Owusu DO, Sarfo FS, Chadwick D, Phillips RO, Beloukas A.

J Clin Virol. 2017 Dec;97:18-21. doi: 10.1016/j.jcv.2017.10.012. Epub 2017 Oct 23.

34.

Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis.

Stockdale AJ, Chaponda M, Beloukas A, Phillips RO, Matthews PC, Papadimitropoulos A, King S, Bonnett L, Geretti AM.

Lancet Glob Health. 2017 Oct;5(10):e992-e1003. doi: 10.1016/S2214-109X(17)30298-X. Review. Erratum in: Lancet Glob Health. 2017 Nov;5(11):e1079.

35.

Out of focus: tailoring the cascade of care to the needs of women living with HIV.

Geretti AM, Loutfy M, D'Arminio Monforte A, Latysheva I, Pérez Elías MJ, Rymer J, Boffito M.

HIV Med. 2017 Sep;18 Suppl 2:3-17. doi: 10.1111/hiv.12533. Review.

36.

The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.

Schultze A, Paredes R, Sabin C, Phillips AN, Pillay D, Mackie N, Castagna A, Chadwick D, Falconer K, Geretti AM, Post FA, Hill T, Kirk O, Pozniak A, Nelson M, Tostevin A, Dunn D, Lundgren J, Cozzi-Lepri A.

Antivir Ther. 2018;23(2):105-116. doi: 10.3851/IMP3178.

PMID:
28627486
37.

Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank.

McLauchlan J, Innes H, Dillon JF, Foster G, Holtham E, McDonald S, Wilkes B, Hutchinson SJ, Irving WL; HCV Research UK Steering Committee.

Int J Epidemiol. 2017 Oct 1;46(5):1391-1391h. doi: 10.1093/ije/dyw362. No abstract available.

38.

Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses.

Burch LS, Smith CJ, Anderson J, Sherr L, Rodger AJ, O'Connell R, Geretti AM, Gilson R, Fisher M, Elford J, Jones M, Collins S, Azad Y, Phillips AN, Speakman A, Johnson MA, Lampe FC.

Lancet Public Health. 2016 Nov;1(1):e26-e36. doi: 10.1016/S2468-2667(16)30002-0.

39.

Accuracy of self-report of HIV viral load among people with HIV on antiretroviral treatment.

Sewell J, Daskalopoulou M, Nakagawa F, Lampe FC, Edwards S, Perry N, Wilkins E, O'Connell R, Jones M, Collins S, Speakman A, Phillips AN, Rodger AJ; Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study Group.

HIV Med. 2017 Aug;18(7):463-473. doi: 10.1111/hiv.12477. Epub 2016 Dec 22.

40.

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.

El Bouzidi K, White E, Mbisa JL, Sabin CA, Phillips AN, Mackie N, Pozniak AL, Tostevin A, Pillay D, Dunn DT; UK HIV Drug Resistance Database; (UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees; UK HIV Drug Resistance Database (UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees.

J Antimicrob Chemother. 2016 Dec;71(12):3487-3494. Epub 2016 Sep 28.

41.

HIV Transmission During Condomless Sex With a Seropositive Partner With Suppressed Infection-Reply.

Geretti AM, Rodger AJ, Lundgren J.

JAMA. 2016 Nov 15;316(19):2045. doi: 10.1001/jama.2016.16033. No abstract available.

PMID:
27838717
42.

No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.

White E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin C, Pillay D, Dunn DT; UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.

J Infect Dis. 2016 Nov 1;214(9):1302-1308. Epub 2016 May 24.

43.

A contaminant-free assessment of Endogenous Retroviral RNA in human plasma.

Karamitros T, Paraskevis D, Hatzakis A, Psichogiou M, Elefsiniotis I, Hurst T, Geretti AM, Beloukas A, Frater J, Klenerman P, Katzourakis A, Magiorkinis G.

Sci Rep. 2016 Sep 19;6:33598. doi: 10.1038/srep33598.

44.

British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015.

Geretti AM, Brook G, Cameron C, Chadwick D, French N, Heyderman R, Ho A, Hunter M, Ladhani S, Lawton M, MacMahon E, McSorley J, Pozniak A, Rodger A.

HIV Med. 2016 Aug;17 Suppl 3:s2-s81. doi: 10.1111/hiv.12424. No abstract available.

45.

Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom.

Tostevin A, White E, Dunn D, Croxford S, Delpech V, Williams I, Asboe D, Pozniak A, Churchill D, Geretti AM, Pillay D, Sabin C, Leigh-Brown A, Smit E; UK HIV Drug Resistance Database.

HIV Med. 2017 Mar;18(3):204-213. doi: 10.1111/hiv.12414. Epub 2016 Aug 1.

46.

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciana P, Gutiérrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, Rieger A, Stoeckle M, Kümmerle T, Bini T, Ammassari A, Gilson R, Krznaric I, Ristola M, Zangerle R, Handberg P, Antela A, Allan S, Phillips AN, Lundgren J; PARTNER Study Group.

JAMA. 2016 Jul 12;316(2):171-81. doi: 10.1001/jama.2016.5148. Erratum in: JAMA. 2016 Aug 9;316(6):667. JAMA. 2016 Nov 15;316(19):2048.

PMID:
27404185
47.

Age, time living with diagnosed HIV infection, and self-rated health.

McGowan JA, Sherr L, Rodger AJ, Fisher M, Miners A, Anderson J, Johnson MA, Elford J, Collins S, Hart G, Phillips AN, Speakman A, Lampe FC; Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study Group.

HIV Med. 2017 Feb;18(2):89-103. doi: 10.1111/hiv.12398. Epub 2016 Jul 7.

48.

Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia.

Nightingale S, Geretti AM, Beloukas A, Fisher M, Winston A, Else L, Nelson M, Taylor S, Ustianowski A, Ainsworth J, Gilson R, Haddow L, Ong E, Watson V, Leen C, Minton J, Post F, Pirmohamed M, Solomon T, Khoo S.

J Neurovirol. 2016 Dec;22(6):852-860. Epub 2016 May 18.

49.

CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF.

Nightingale S, Michael BD, Fisher M, Winston A, Nelson M, Taylor S, Ustianowski A, Ainsworth J, Gilson R, Haddow L, Ong E, Leen C, Minton J, Post F, Beloukas A, Borrow R, Pirmohamed M, Geretti AM, Khoo S, Solomon T.

Cytokine. 2016 Jul;83:139-146. doi: 10.1016/j.cyto.2016.04.004. Epub 2016 Apr 28.

50.

Sexual behaviour among people with HIV according to self-reported antiretroviral treatment and viral load status.

Lampe FC; Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study Group.

AIDS. 2016 Jul 17;30(11):1745-59. doi: 10.1097/QAD.0000000000001104.

Supplemental Content

Loading ...
Support Center